2 citations
,
May 2016 in “Journal of Clinical Oncology” This study found that topical BPM31543 was safe, tolerable, and showed potential to reduce chemotherapy-induced alopecia at higher dosing levels among adult women with cancer receiving taxane-based chemotherapy.
May 2019 in “Journal of clinical oncology” This Phase 1 study reported that topical application of BPM31543 was safe and well-tolerated in patients receiving taxane-based chemotherapy, with some experiencing less than 50% hair loss, suggesting potential efficacy in reducing chemotherapy-induced alopecia, although no maximum tolerated dose was identified.
51 citations
,
January 2012 in “Annals of dermatology/Annals of Dermatology” This case report describes a 7-year-old boy with alopecia areata and reduced vitamin D receptor expression whose condition improved after using calcipotriol, a strong vitamin D analog.
39 citations
,
January 2017 in “Dermatologic Therapy” This study found that topical calcipotriol lotion resulted in hair regrowth in 59.1% of alopecia areata patients, with better response observed in those with lower serum vitamin D levels.
38 citations
,
June 2015 in “PubMed” This study found that topical calcipotriol may safely and effectively treat mild-to-moderate patchy alopecia areata, with significant hair regrowth observed in the majority of participants over 12 weeks.